(Q41720185)

8 October 2017

1 reference

title

Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent (English)

1 reference

8 October 2017

1 reference

Collen D

1

1 reference

PubMed ID

9500599

8 October 2017

language of work or name

English

0 references

publication date

1 March 1998

1 reference

8 October 2017

1 reference

8 October 2017

4

1 reference

8 October 2017

3

1 reference

8 October 2017

279-284

1 reference

https://scigraph.springernature.com/pub.10.1038/nm0398-279

8 October 2017

0 references

cites work

Fibrin-selective thrombolytic therapy for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

STREPTOCOCCAL FIBRINOLYSIS: A PROTEOLYTIC REACTION DUE TO A SERUM ENZYME ACTIVATED BY STREPTOCOCCAL FIBRINOLYSIN

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

Reperfusion in acute myocardial infarction. International Society and Federation of Cardiology and World Health Organization Task Force on Myocardial Reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Staphylokinase; an activator of plasma protease.

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Staphlococcal Coagulation and Fibrinolysis

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

EFFECTS OF FIBRINOLYTIC AGENTS AND HEPARIN ON INTRAVASCULAR CLOT LYSIS

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Cloning and expression of the staphylokinase gene of Staphylococcus aureus in Escherichia coli

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Cloning and expression in Escherichia coli, Bacillus subtilis, and Streptococcus sanguis of a gene for staphylokinase--a bacterial plasminogen activator.

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Nucleotide sequence of the staphylokinase gene fromStaphylococcus aurens

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Three-dimensional structure of staphylokinase, a plasminogen activator with therapeutic potential

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Staphylokinase requires NH2-terminal proteolysis for plasminogen activation

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Interactions between staphylokinase, plasmin(ogen), and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of alpha 2-plasmin inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

On the molecular interactions between plasminogen-staphylokinase, alpha 2-antiplasmin and fibrin

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Comparative antigenicity of recombinant wild-type staphylokinase (SakSTAR) and a selected mutant (SakSTAR.M38) in a baboon thrombolysis model

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patterns

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Recombinant staphylokinase variants with altered immunoreactivity. IV: Identification of variants with reduced antibody induction but intact potency

1 reference

https://api.crossref.org/works/10.1038%2FNM0398-279

7 January 2021

Identifiers

DOI

10.1038/NM0398-279

1 reference

PubMed ID

9500599

Dimensions Publication ID

8 October 2017

0 references

1 reference

PubMed ID

9500599